. 2020 Oct 13;5(5):e000876. doi: 10.1136/esmoopen-2020-000876

Table 3.

OS univariate Cox model

Variable	Group	n	HR	95 CI	P value
# Sites	>2	24	1.00	0.42 to 1.65	0.61
# Sites	≤2	17	0.84	0.42 to 1.65	0.61
Sites	Visceral	35	1.00	0.34 to 2.26	0.78
Sites	Bone/soft tissue	6	0.87	0.34 to 2.26	0.78
# Lines	>2	31	1.00	0.66 to 2.94	0.39
# Lines	2	10	1.39	0.66 to 2.94	0.39
TGF-β (T₀)	>Median	20	1.00	0.38 to 1.45	0.38
TGF-β (T₀)	≤Median	21	0.74	0.38 to 1.45	0.38
TGF-β (T₁)	>Median	20	1.00	0.32 to 1.22	0.17
TGF-β (T₁)	≤Median	21	0.62	0.32 to 1.22	0.17
TNF-α (T₀)	>Median	20	1.00	0.58 to 2.18	0.75
TNF-α (T₀)	≤Median	21	1.12	0.58 to 2.18	0.75
TNF-α (T₁)	>Median	20	1.00	0.43 to 1.61	0.58
TNF-α (T₁)	≤Median	21	0.83	0.43 to 1.61	0.58
VEGF (T₀)	>Median	20	1.00	0.67 to 2.70	0.40
VEGF (T₀)	≤Median	21	1.35	0.67 to 2.70	0.40
VEGF (T₁)	>Median	20	1.00	0.64 to 2.42	0.53
VEGF (T₁)	≤Median	21	1.24	0.64 to 2.42	0.53
IL-6 (T₀)	>Median	20	1.00	0.16 to 0.70	0.004
IL-6 (T₀)	≤Median	21	0.34	0.16 to 0.70	0.004
IL-6 (T₁)	>Median	20	1.00	0.20 to 0.78	0.007
IL-6 (T₁)	≤Median	21	0.39	0.20 to 0.78	0.007
IL-8 (T₀)	>Median	20	1.00	0.17 to 0.70	0.03
IL-8 (T₀)	≤Median	21	0.35	0.17 to 0.70	0.03
IL-8 (T₁)	>Median	20	1.00	0.14 to 0.58	<0.001
IL-8 (T₁)	≤Median	21	0.29	0.14 to 0.58	<0.001
IL-10 (T₀)	>Median	20	1.00	0.28 to 1.07	0.08
IL-10 (T₀)	≤Median	21	0.55	0.28 to 1.07	0.08
IL-10 (T₁)	>Median	20	1.00	0.30 to 1.16	0.13
IL-10 (T₁)	≤Median	21	0.59	0.30 to 1.16	0.13
IL-21 (T₀)	>Median	20	1.00	0.59 to 2.29	0.66
IL-21 (T₀)	≤Median	21	1.17	0.59 to 2.29	0.66
IL-21 (T₁)	>Median	20	1.00	0.55 to 2.12	0.81
IL-21 (T₁)	≤Median	21	1.09	0.55 to 2.12	0.81
CCL-2 (T₀)	>Median	20	1.00	0.36 to 1.36	0.29
CCL-2 (T₀)	≤Median	21	0.70	0.36 to 1.36	0.29
CCL-2 (T₁)	>Median	20	1.00	0.31 to 1.55	0.37
CCL-2 (T₁)	≤Median	21	0.70	0.31 to 1.55	0.37

CCL-2, C-C motif chemokine ligand-2; IL, interleukin; OS, overall survival; TGF-β, transforming growth factor β; TNF-α, tumour necrosis factor α; VEGF, vascular endothelial growth factor.